---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178463"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T15:02:37.332299+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru Q3 net loss narrows to $0.50/sh; enobosarm Phase 2b data show lean mass preservation

## Summary
- Net loss from continuing ops $7.3M ($0.50/sh) vs $10.3M ($0.71/sh) in Q3 2024.
- R&D expense $3.0M, down from $4.8M; SG&A $5.0M, down from $5.8M.
- Cash $15.0M at June 30, 2025 vs $24.9M at Sep 30, 2024; burn funds clinical programs.
- Phase 2b QUALITY: enobosarm 3mg + semaglutide preserved 100% lean mass (p<0.001) and increased fat loss 12% vs semaglutide alone.
- Maintenance Extension: enobosarm 3mg monotherapy reduced weight regain by 46% after semaglutide discontinuation.

## SEC filing metadata
- accession: 0001193125-25-178463
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/0001193125-25-178463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/d59822d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178463
- JSON: https://secwatch.observer/filing/0001193125-25-178463.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.